The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

about

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.

P2860

Q33433565-458B9AB9-F796-4836-BDF5-87947BD939B4 Q46006814-46040F24-A890-4FF6-88AA-D561F9335721

P2860

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q38198754

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

@en

type

Item

label

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

@en

prefLabel

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

@en

P1476

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma

@en

P2093

Alessandra Dondi

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

Peripheral T-cell non-Hodgkin's lymphoma

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

P304

711-718

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.902050

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24661228

http://www.w3.org/2001/XMLSchema#string

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

about

P2860

P2860

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698